Back to Agenda
Accelerating US Based Domestic Manufacturing by Leveraging Innovative Regulatory Concepts
Session Chair(s)
Joseph Kutza, PHD
Senior Director Regulatory Policy - CMC
Eli Lilly and Company, United States
The recent focus by the US government to increase US-based pharmaceutical manufacturing has created opportunities to revisit the regulations and guidelines that lead to the lengthy time that it takes to construct or expand a manufacturing facility.
Learning Objective : Understand critical path items that lead to extended construction and regulatory approval timelines; Explore how FDA's innovative regulatory concepts address these challenges; Identify the similarities and differences between bolstering domestic manufacturing by onshoring manufacturing to established facilities versus new or expanded US based facilities.
Have an account?